|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM342594885 |
| 003 |
DE-627 |
| 005 |
20231226014457.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202203958
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1141.xml
|
| 035 |
|
|
|a (DE-627)NLM342594885
|
| 035 |
|
|
|a (NLM)35738390
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zou, Yan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.08.2022
|
| 500 |
|
|
|a Date Revised 19.08.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Glioblastoma (GBM) is an intractable malignancy with high recurrence and mortality. Combinatorial therapy based on temozolomide (TMZ) and cisplatin (CDDP) shows promising potential for GBM therapy in clinical trials. However, significant challenges include limited blood-brain-barrier (BBB) penetration, poor targeting of GBM tissue/cells, and systemic side effects, which hinder its efficacy in GBM therapy. To surmount these challenges, new GBM-cell membrane camouflaged and pH-sensitive biomimetic nanoparticles (MNPs) inspired by the fact that cancer cells readily pass the BBB and localize with homologous cells, are developed. This study's results show that MNPs can efficiently co-load TMZ and CDDP, transport these across the BBB to specifically target GBM. Incorporation of pH-sensitive polymer then allows for controlled release of drug cargos at GBM sites for combination drug therapy. Mice bearing orthotopic U87MG or drug-resistant U251R GBM tumor and treated with MNPsTMZ+CDDP show a potent anti-GBM effect, greatly extending the survival time relative to mice receiving single-drug loaded nanoparticles. No obvious side effects are apparent in histological analyses or blood routine studies. Considering these results, the study's new nanoparticle formulation overcomes multiple challenges currently limiting the efficacy of combined TMZ and CDDP GBM drug therapy and appears to be a promising strategy for future GBM combinatorial chemotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a biomimetics
|
| 650 |
|
4 |
|a blood-brain barrier
|
| 650 |
|
4 |
|a brain delivery
|
| 650 |
|
4 |
|a combinational chemotherapy
|
| 650 |
|
4 |
|a glioblastoma
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 650 |
|
7 |
|a Temozolomide
|2 NLM
|
| 650 |
|
7 |
|a YF1K15M17Y
|2 NLM
|
| 700 |
1 |
|
|a Wang, Yibin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Sen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Yanjie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yin, Jinlong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lovejoy, David B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, Meng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Xing-Jie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Jong Bae
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Efremov, Yuri M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ulasov, Ilya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Bingyang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 33 vom: 10. Aug., Seite e2203958
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:33
|g day:10
|g month:08
|g pages:e2203958
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202203958
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 33
|b 10
|c 08
|h e2203958
|